MetaCap

LeonaBio (LONA) vs Metagenomi Therapeutics (MGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

LeonaBio (LONA) has outperformed Metagenomi Therapeutics (MGX) over the past year, losing 56.1% versus a loss of 62.6%. LeonaBio is the larger company by market cap ($26.4 million vs $21.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LONA-56.13%MGX-62.58%
+164%+46%-73%
Nov 21, 20251 yearNov 20, 2026
LONA-93.92%MGX-94.52%
+24%-38%-100%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LONA versus MGX key metrics
MetricLONAMGX
Share price$2.02$0.565
Market cap$26.41M$21.36M
1-day change-17.89%-7.95%
YTD return-73.32%-65.12%
1-year return-56.13%-62.58%
5-year return-98.55%—
EPS (TTM)$-22.20$-2.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$25.21M
Revenue growth (YoY)—-51.79%
Net income (latest FY)$-105.61M$-87.87M
Operating margin—-380.85%
Net margin—-348.54%
52-week high$14.21$1.87
52-week low$1.91$0.562
Distance from 52-week high-85.78%-69.79%
Analyst consensusnonestrong_buy
Avg. price target upside+757.92%+1138.94%
Average volume195.37K163.21K
Shares outstanding13.08M37.81M
Employees19113
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About LeonaBio

LONA stock →

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees

About Metagenomi Therapeutics

MGX stock →

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

LONA vs MGX FAQ

Which is bigger, LeonaBio or Metagenomi Therapeutics?

LeonaBio (LONA) is larger, with a market capitalization of $26.41M compared with $21.36M for Metagenomi Therapeutics (MGX).

Which stock has performed better over the past year, LONA or MGX?

LONA returned -56.13% over the past 12 months, compared with -62.58% for MGX (price return, excluding dividends). Past performance does not predict future results.

Are LeonaBio and Metagenomi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons